Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesClinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09
Ruiz-Irastorza G et al. – Review concludes that hydroxychloroquine (HCQ) should be given to most patients with systemic lupus erythematosus (SLE) during the whole course of the disease, irrespective of its severity, and be continued during pregnancy.
Methods- An analysis of all the published evidence of the beneficial and adverse effects of antimalarial drugs (AM) therapy in SLE
- Systematic review: between 1982-2007 using MEDLINE and EMBASE
- Randomised controlled trials (RCTs) and observational studies were selected
- Case reports were excluded except for toxicity reports
- GRADE system was used to analyse the quality of the evidence
- 95 articles were included in the systematic review
- High evidence that AM prevent lupus flares and increase long-term survival of SLE pts
- Moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss
- Toxicity related to AM was infrequent, mild and usually reversible, with HCQ having a safer profile
- In pregnant women, high evidence that AM, particularly HCQ, decrease lupus activity w/o harming the baby
- Evidence supporting an effect on severe lupus activity, lipid levels and subclinical atherosclerosis was weak
- Individual papers suggest effects in preventing the evolution from SLE-like to full-blown SLE, influencing vit D levels and protecting lupus pts against cancer
GUILLERMO RUIZ-IRASTORZA, 06/09/09
| This systematic review analysed the available evidence on the use of antimalarials in SLE. Data confirmed them as very effective and safe drugs for the treatment of lupus, with important long-term effects, including a decrease in mortality. More recenta data, published after this review, reinforce the role of antimalarials in preventing thrombosis, also in patients with antiphospholipid antibodies, and in preventing infections. Given the efficacy and safety profile, patients with SLE should be treated long term with hydroxiychloroquine. |
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Today in Systemic Lupus (SLE)...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus
Journal of Rheumatology, 10/19/09
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
Arthritis Research & Therapy, 10/16/09
Diffusion-weighted MR imaging of kidneys in patients with systemic lupus erythematosus: initial experience
Rheumatology International, 10/14/09
Sponsor
Article Search
Sponsor